Cyclophosphamide (cyclophosphamide)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Cyclophosphamide, a nitrogen mustard-derivative, polyfunctional alkylating agent, is an antineoplastic agent and immunosuppressant.
USES: Cyclophosphamide is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cell growth. Cyclophosphamide also works by decreasing your immune system's response to various diseases.
It is used to treat a certain type of kidney disease in children after other treatments have not worked.
Generic name: cyclophosphamide
Pronunciation: (sye-klo-FOSS-fuh-mide)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Cyclophosphamide
Indications
The following indications are listed for Cyclophosphamide:
- Acute Lymphoid Leukemia
- Acute Monocytic Leukemia
- Acute Myeloid Leukemia
- Burkitt's Lymphoma
- Carcinoma Of Breast
- Chronic Lymphoid Leukemia
- Cutaneous T-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Hodgkin's Lymphoma
- Malignant Neoplasm Of The Ovary
- Minimal Change Glomerulonephritis
- Multiple Myeloma
- Mycosis Fungoides
- Neuroblastoma
- Non-Hodgkin's Lymphoma
- Progressive Chronic Lymphocytic Leukemia
- Retinoblastoma
Also known as: Acute Granulocytic Leukemia, Acute Leukemic Myelosis, Acute Lymphatic Leukemia, Acute Lymphocytic Leukemia, Acute Lymphogenous Leukemia, Acute Myelocytic Leukemia, Acute Myelogenic Leukemia, Acute Myelogenous Leukemia, Acute Non-Lymphoblastic Leukemia, Acute Non-Lymphocytic Leukemia, Anemia Lymphatica, Breast Carcinoma, Burkitt's Tumor, Follicular B-Cell Lymphoma, Follicular B-Cell Non-Hodgkin's Lymphoma, Glioma Retinae, Hodgkin's Disease, Lipoid Nephrosis, Lymphoblastic Leukemia, Malignant Neoplasm Of Ovary, Malignant Tumor Of The Ovary, Minimal Change Disease, Minimal Change Nephropathy, Minimal Change Nephrotic Syndrome, Monocytic Leukemia, Neuroblastoma Sympathicum, Non-Hodgkin's Type Lymphoma, Ovarian Cancer, Ovarian Malignancy, Plasma Cell Myeloma, Primary Cutaneous T-Cell Lymphoma, Progressive Cll, Refractory Chronic Lymphocytic Leukemia, Refractory Cll, Schilling's Leukemia, Small Cerebriform Cell Lymphoma, Sympathicoblastoma, Sympathicogonioma.
Dosing
Because of the risk of certain toxicities (e.g., cardiotoxicity) and overdosage with high doses of cyclophosphamide, particular care should be taken to ensure that correct dosages and administration schedules have been prescribed and appropriate monitoring instituted when higher than usual dosages (e.g., those employed under protocol conditions) are encountered.
Clinicians should consult published protocols for the dosage of cyclophosphamide and other chemotherapeutic agents in combination regimens and the method and sequence of administration.
The effects of renal or hepatic impairment on the elimination of cyclophosphamide have not been elucidated. The manufacturers recommend caution and careful monitoring for toxicity in patients with renal and/or hepatic impairment, but makes no specific recommendations for adjustment of cyclophosphamide dosage. Measurable changes in pharmacokinetic parameters for cyclophosphamide may be observed in patients with renal impairment, but there is no consistent evidence demonstrating the need for dosage adjustment.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Cyclophosphamide can cause fetal toxicity when administered to pregnant women, but potential benefits from use of the drug may be acceptable in certain conditions despite the possible risks to the fetus. Abnormalities, including ectrodactylia, have occurred in infants born to women treated with the drug during pregnancy. Normal infants also have been born to women who received cyclophosphamide, including during the first trimester. Cyclophosphamide should be used during pregnancy only in life-threatening situations or severe disease for which safer drugs cannot be used or are ineffective. When the drug is administered during pregnancy or if the patient becomes pregnant while receiving cyclophosphamide, the patient should be informed of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
Cyclophosphamide is distributed into milk. Because of the potential for serious adverse reactions to cyclophosphamide in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.